ArticleInternational journal of nanomedicine2018
Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy.Current issues in molecular biology · 2025Review
- Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing.Small science · 2024Article
- Immune-related adverse events of antibody-based biological medicines in cancer therapy.Journal of cellular and molecular medicine · 2024Review
- Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment.Biomaterials research · 2024Article
- Vector enabled CRISPR gene editing - A revolutionary strategy for targeting the diversity of brain pathologies.Coordination chemistry reviews · 2023Article
- Intelligent nanotherapeutic strategies for the delivery of CRISPR system.Acta pharmaceutica Sinica. B · 2023Review
- Silk-Gel Powered Adenoviral Vector Enables Robust Genome Editing of PD-L1 to Augment Immunotherapy across Multiple Tumor Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- BSA-PEI Nanoparticle Mediated Efficient Delivery of CRISPR/Cas9 into MDA-MB-231 Cells.Molecular biotechnology · 2022Article
- Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA.Scientific reports · 2022Article
- Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology.Royal Society open science · 2022Review
- Lipid- and Polymer-Based Nanoparticle Systems for the Delivery of CRISPR/Cas9.Journal of drug delivery science and technology · 2021Article
- Nanomedicine-based cancer immunotherapy: recent trends and future perspectives.Cancer gene therapy · 2021Review
- Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants.International journal of molecular sciences · 2021Review
- Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions.Cancers · 2021Review
- Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas.International journal of nanomedicine · 2021Article
- Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing.Pharmaceutics · 2020Review
- Progress and challenges in CRISPR-mediated therapeutic genome editing for monogenic diseases.Journal of biomedical research · 2020Article
- Polyethylenimine based magnetic nanoparticles mediated non-viral CRISPR/Cas9 system for genome editing.Scientific reports · 2020Article
- RNA Nanotechnology-Mediated Cancer Immunotherapy.Theranostics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, a double emulsion method for complexing plasmids with stearyl poly-ethylenimine ( MATERIALS AND
methodsChemically synthesized stearyl-polyethyenimine (
results
conclusionThe plasmids/
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.